Serwanga, J.; Kato, L.; Oluka, G.K.; Ankunda, V.; Sembera, J.; Baine, C.; Kitabye, I.; Namuyanja, A.; Opio, S.; Katende, J.S.; et al. The Single-Dose Janssen Ad26.COV2.S COVID-19 Vaccine Elicited Robust and Persistent Anti-Spike IgG Antibody Responses in a 12-Month Ugandan Cohort. Frontiers in Immunology 2024, 15, doi:10.3389/fimmu.2024.1384668.
Serwanga, J.; Kato, L.; Oluka, G.K.; Ankunda, V.; Sembera, J.; Baine, C.; Kitabye, I.; Namuyanja, A.; Opio, S.; Katende, J.S.; et al. The Single-Dose Janssen Ad26.COV2.S COVID-19 Vaccine Elicited Robust and Persistent Anti-Spike IgG Antibody Responses in a 12-Month Ugandan Cohort. Frontiers in Immunology 2024, 15, doi:10.3389/fimmu.2024.1384668.
Serwanga, J.; Kato, L.; Oluka, G.K.; Ankunda, V.; Sembera, J.; Baine, C.; Kitabye, I.; Namuyanja, A.; Opio, S.; Katende, J.S.; et al. The Single-Dose Janssen Ad26.COV2.S COVID-19 Vaccine Elicited Robust and Persistent Anti-Spike IgG Antibody Responses in a 12-Month Ugandan Cohort. Frontiers in Immunology 2024, 15, doi:10.3389/fimmu.2024.1384668.
Serwanga, J.; Kato, L.; Oluka, G.K.; Ankunda, V.; Sembera, J.; Baine, C.; Kitabye, I.; Namuyanja, A.; Opio, S.; Katende, J.S.; et al. The Single-Dose Janssen Ad26.COV2.S COVID-19 Vaccine Elicited Robust and Persistent Anti-Spike IgG Antibody Responses in a 12-Month Ugandan Cohort. Frontiers in Immunology 2024, 15, doi:10.3389/fimmu.2024.1384668.
Abstract
The study evaluated the immune response to the Janssen Ad26.COV2.S COVID-19 vaccine in a Ugandan cohort, focusing on spike (S) and nucleocapsid (N) protein-directed antibodies. The aim was to assess the longevity and robustness of the elicited antibodies, aligning with breakthrough infections and prior exposure to SARS-CoV-2. The study involved 319 specimens collected over 12 months from 60 vaccinees aged 18 to 64. Binding antibodies were quantified using a validated ELISA method to measure SARS-CoV-2-specific IgG, IgM, and IgA levels against the S and N proteins. The results showed that baseline seropositivity for S-IgG was high at 67%, increasing to 98% by day 14 and consistently stayed above 95% for up to 12 months. However, S-IgM responses remained suboptimal. An increased S-IgA serpositivity rate doubled from 40% at baseline to 86% just two weeks following the initial vaccine dose, indicating sustained and robust mucosal immunity. An increase in N-IgG levels at nine months post-vaccination suggested breakthrough infections in eight cases. Baseline cross-reactivity influenced spike-directed antibody responses, with those with pre-existing S-IgG antibodies showing higher responses. The vaccine demonstrated robust and long-lasting immune responses, with significant implications for regions where administering follow-up doses is challenging.
Biology and Life Sciences, Immunology and Microbiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
